Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefadroxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | HPGD | P15428 | 3/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefadroxil SCHEMBL6438517 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL16072813 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL3984782 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL524155 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL19123520 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL151320 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9650920 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL13698957 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9807365 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL1821440 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE31730-E | Process for the preparation of the crystalline monohydrate of 7-(D-α-aα-(p-hydroxyphenyl)acetamido)-3-methyl-3-cephem-4-carboxylic acid | BRISTOL-MYERS COMPANY (US) | 1984-11-13 | — | — | US | claimed |
| US-4391974-A | LYSINE SALT, CEPHALOSPORINS | LIOFILIZACIONES ESTERILIZACIONES Y SINTHESIS S.A. (ES) | 1983-07-05 | — | — | US | claimed |
| US-4234721-A | Process for the preparation of the crystalline monohydrate of 7-[D-amino-(p-hydroxyphenyl]acetamido)-3-methyl-3-cephen-4-carboxylic acid | BRISTOL-MYERS COMPANY (US) | 1980-11-18 | — | — | US | claimed |
| US-4160863-A | ANTIBIOTIC | BRISTOL-MYERS COMPANY (US) | 1979-07-10 | — | — | US | claimed |
| US-20090221815-A1 | PROCESSES FOR THE PREPARATION OF CEPHEM DERIVATIVES | CJ CHEILJEDANG CORPORATION (KR) | 2009-09-03 | — | — | US | disclosed |
| US-7544797-B2 | Processes for the preparation of cephem derivatives | CJ CHEILJEDANG CORPORATION (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070060747-A1 | Processes for the preparation of cephem derivatives | CJ CORPORATION (KR) | 2007-03-15 | — | — | US | disclosed |
| WO-2004035593-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CEFADROXIL | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-04-29 | — | — | WO | disclosed |
| US-20040077849-A1 | Process for the preparation of cefadroxil | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-04-22 | — | — | US | disclosed |
| US-6337396-B1 | CEPHALOSPORIN ANTIBIOTICS | RANBAXY LABORATORIES LIMITED (IN) | 2002-01-08 | — | — | US | disclosed |
| EP-0690864-B1 | CRYSTALLINE CEFTIOFUR FREE ACID | UPJOHN CO (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-0690864-A1 | CRYSTALLINE CEFTIOFUR FREE ACID | PHARMACIA & UPJOHN COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0000393-A1 | Beta-lactam compounds, process for their preparation and their use | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
| US-4107304-A | Oxo-imidazolidine substituted cephalosporins and antibacterial compositions and methods of combatting bacteria employing them | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-15 | — | — | US | disclosed |
| US-4093722-A | ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4086340-A | ANTIBIOTIC; ANIMAL GROWTH PROMOTER | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-25 | — | — | US | disclosed |
| US-4086341-A | NITRO SUBSTITUTED; ANTIBIOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-25 | — | — | US | disclosed |
| US-4029806-A | Nitro-β-lactam antibiotics and processes for their preparation and use | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-14 | — | — | US | disclosed |
| US-4012518-A | PENICILLIN DERIVATIVES AS GROWTH AND FEED UTILIZATION PROMOTERS IN ANIMALS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-15 | — | — | US | disclosed |
| US-3985741-A | Production of p-hydroxycephalexin | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060747-A1 | Processes for the preparation of cephem derivatives | CEP170, HAMP, NISCH | MAPT 1430/4885HSD17B10 1307/4885KMT2A 2733/4885 |
| US-20040077849-A1 | Process for the preparation of cefadroxil | CFD, CYP2F1, CYP2W1 | MAPT 4152/4885HSD17B10 519/4885KMT2A 3271/4885 |
| US-20090221815-A1 | PROCESSES FOR THE PREPARATION OF CEPHEM DERIVATIVES | CEP170, HAMP, NISCH | MAPT 1430/4885HSD17B10 1307/4885KMT2A 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.